Estimated to represent less than 5% of all asthmatic patients, children with severe asthma
experience troublesome persistent symptoms, life-threatening attacks and side effects by oral
corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An
accurate understanding of the mechanisms of the disease has been crucial for the discovery and
development of biological therapies, for which children with severe asthma are candidates. The aim
of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence
of novel targeted therapies in the pediatric age range.
Keywords: Benralizumab, children, dupilumab, mepolizumab, omalizumab, reslizumab, severe asthma.
Licari A, Manti S, Castagnoli R, et al. Immunomodulation in Pediatric
Asthma. Front Pediatr 2019 Jul 12; 7: 289. doi:
10.3389/fped.2019.00289. eCollection 2019. Review. PubMed
PMID: 31355170; PubMed Central PMCID: PMC6640202
Rights & PermissionsPrintExport